To assess the influence of inflammatory plasma biomarkers on choroidal thickness (CT) in patients with type 2 diabetes (T2D).
Methods
Cross-sectional study enrolling T2D patients and age-matched healthy controls (>55 years of age, Caucasian, axial length <26 mm, no macular edema, and naïve). Patients were examined with swept-source OCT Triton, obtaining automatic measurements. CT was analyzed using the ETDRS grid and the recently proposed choroidal division. A blood analysis was commanded: general biochemical profile, liver status, T2D status, thyroid and parathyroid activity, coagulation, general immunological profile, and inflammatory biomarkers.
Results
124 eyes of 124 patients with a mean age between 66 and 68 years were examined. The new choroidal division showed differences between groups (p < 0.05) in more sectors than the ETDRS grid, and more biomarkers influenced these new sectors. T2D patients had higher levels of IL-8, TNF-α, MCP1, adiponectin and L-selectin. CT was influenced by TNF-α, IL-17, leukocytes and erythrocyte sedimentation rate, as well as by HDL cholesterol, albumin, liver function biomarkers, and TSH. HbA1c showed little influence on CT.
Conclusions
T2D patients present increased plasma inflammatory biomarkers, exhibiting an influence on CT. IL-17 is related to a thicker choroid but TNF-α is related to a thinner choroid. HbA1c has little influence on CT. The recently proposed choroidal division is more sensitive to CT changes than the ETDRS grid. Some sectors are more sensitive to plasma biomarkers.
GuthrieRAGuthrieDW. Pathophysiology of diabetes Mellitus. Crit Care Nurs Q. 2004; 27: 113–125.
2.
KahnSECooperMEDel PratoS. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014; 383: 1068–1083.
3.
KolluruGKBirSCKevilCG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2012; 2012: 1–30.
4.
CalleMCFernandezML. Inflammation and type 2 diabetes. Diabetes Metab. 2012; 38: 183–191.
5.
KaštelanSOreškovićIBišćanF,et al.Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Medica. 2020; 30: 1–15.
6.
GouliopoulosNSKalogeropoulosCLavarisA, et al. Association of serum inflammatory markers and diabetic retinopathy: a review of literature. Eur Rev Med Pharmacol Sci. 2018; 22: 7113–7128.
7.
Bartol-PuyalFDAIsantaCRuiz-MorenoÓ, et al. Distribution of choroidal thinning in high myopia, diabetes mellitus, and aging: a swept-source OCT study. J Ophthalmol. 2019; 2019: 1–9.
8.
QuerquesGLattanzioRQuerquesL, et al. Enhanced depth imaging optical coherence tomography in type 2 diabetes. Investig Opthalmol Vis Sci. 2012; 53: 6017.
9.
EsmaeelpourMPovažayBHermannB, et al. Mapping choroidal and retinal thickness variation in type 2 diabetes using three-dimensional 1060-nm optical coherence tomography. Invest Ophthalmol Vis Sci. 2011; 52: 5311–5316.
10.
EndoHKaseSSaitoM, et al. Choroidal thickness in diabetic patients without diabetic retinopathy: a meta-analysis. Am J Ophthalmol. 2020; 218: 68–77.
11.
KimJTLeeDHJoeSG,et al.Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013; 54: 3378–3384.
12.
EliwaTFHegazyOSMahmoudSS,et al.Choroidal thickness change in patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2017; 48: 970–977.
13.
XuJXuLDuKF, et al. Subfoveal choroidal thickness in diabetes and diabetic retinopathy. Ophthalmology. 2013; 120: 2023–2028.
14.
Ruiz-MedranoJFlores-MorenoIPeña-GarcíaP,et al.Macular choroidal thickness profile in a healthy population measured by swept-source optical coherence tomography. Investig Ophthalmol Vis Sci. 2014; 55: 3532–3542.
15.
PabloLECameoBBamboMP, et al. Peripapillary choroidal thickness analysis using swept-source optical coherence tomography in glaucoma patients: a broader approach. Ophthalmic Res. 2018; 59: 7–13.
16.
ZhangQNeitzMNeitzJ,et al.Geographic mapping of choroidal thickness in myopic eyes using 1050-nm spectral domain optical coherence tomography. J Innov Opt Health Sci. 2015; 8: 1550012.
17.
ParkJYKangM-JKimBG, et al. Topographic changes in choroidal thickness in age-related macular degeneration during the development of active choroidal neovascularization. Retina. 2021; 41: 409–422.
American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013; 36: S11–S66.
20.
MatsuoYSakamotoTYamashitaT,et al.Comparisons of choroidal thickness of normal eyes obtained by two different spectral-domain OCT instruments and one swept-source OCT instrument. Investig Ophthalmol Vis Sci. 2013; 54: 7630–7636.
21.
AbadíaBCalvoPBartol-PuyalF,et al.Repeatability of choroidal thickness measurements assessed with swept-source optical coherence tomography in healthy and diabetic individuals. Retina. 2019; 39: 786–793.
22.
MansouriKMedeirosFATathamAJ,et al.Evaluation of retinal and choroidal thickness by swept-source optical coherence tomography: repeatability and assessment of artifacts. Am J Ophthalmol. 2014; 157: 1022–1032.e3.
23.
VujosevicSMidenaE. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and Müller cells alterations. J Diabetes Res. 2013; 2013: 1–8.
24.
SchröderKSzendroediJBenthinA, et al. German diabetes study - baseline data of retinal layer thickness measured by SD-OCT in early diabetes mellitus. Acta Ophthalmol. 2019; 97: e303–e307.
25.
Bartol-PuyalFDAIsantaCCalvoP,et al.Macro and microangiopathy related to retinopathy and choroidopathy in type 2 diabetes. Eur J Ophthalmol. 2022; 32: 2412–2418.
26.
SabanayagamCCheeMLBanuR, et al. Association of diabetic retinopathy and diabetic kidney disease with all-cause and cardiovascular mortality in a multiethnic Asian population. JAMA Netw Open. 2019; 2: e191540.
27.
WangYWanHChenY, et al. Association of C-peptide with diabetic vascular complications in type 2 diabetes. Diabetes Metab. 2020; 46: 33–40.
28.
ForresterJVKuffovaLDelibegovicM. The role of inflammation in diabetic retinopathy. Front Immunol. 2020; 11: 583687.
LiSFuX-AZhouX-F,et al.Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy. Int J Ophthalmol. 2012; 5: 726–730.
KimMKimRYParkY-H. Choroidal vascularity index and choroidal thickness in human leukocyte antigen-B27-associated uveitis. Ocul Immunol Inflamm. 2019; 27: 1280–1287.
33.
GuoSYinHZhengM, et al. Cytokine profiling reveals increased serum inflammatory cytokines in idiopathic choroidal neovascularization. BMC Ophthalmol. 2019; 19. DOI: 10.1186/S12886-019-1101-6.
34.
JasielskaMSemkovaIShiX, et al. Differential role of tumor necrosis factor (TNF)-alpha receptors in the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010; 51: 3874–3883.
35.
Sahinoglu-KeskekNAltan-YayciogluRCananH,et al.Influence of glycosylated hemoglobin on the choroidal thickness. Int Ophthalmol. 2018; 38: 1863–1869.
36.
UnsalEEltutarKZirtiloğluS,et al.Choroidal thickness in patients with diabetic retinopathy. Clin Ophthalmol. 2014; 8: 637–642.
37.
OkamotoMMatsuuraTOgataN. Effects of panretinal photocoagulation on choroidal thickness and choroidal blood flow in patients with severe nonproliferative diabetic retinopathy. Retina. 2016; 36: 805–811.
38.
KimJHLeeTGChangYS,et al.Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Br J Ophthalmol. 2016; 100: 1634–1639.
39.
GabrielMEsmaeelpourMShams-MafiF, et al. Mapping diurnal changes in choroidal, Haller’s and Sattler’s layer thickness using 3–dimensional 1060-nm optical coherence tomography. Graefe’s Arch Clin Exp Ophthalmol. 2017; 255: 1957–1963.
